"Neoadjuvant Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
| Descriptor ID |
D020360
|
| MeSH Number(s) |
E02.186.450
|
| Concept/Terms |
Neoadjuvant Therapy- Neoadjuvant Therapy
- Neoadjuvant Therapies
- Therapies, Neoadjuvant
- Therapy, Neoadjuvant
- Neoadjuvant Treatment
- Neoadjuvant Treatments
- Treatment, Neoadjuvant
- Treatments, Neoadjuvant
|
Below are MeSH descriptors whose meaning is more general than "Neoadjuvant Therapy".
Below are MeSH descriptors whose meaning is more specific than "Neoadjuvant Therapy".
This graph shows the total number of publications written about "Neoadjuvant Therapy" by people in this website by year, and whether "Neoadjuvant Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 3 | 4 |
| 2000 | 0 | 2 | 2 |
| 2001 | 1 | 2 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 2 | 3 |
| 2004 | 2 | 1 | 3 |
| 2005 | 0 | 3 | 3 |
| 2006 | 1 | 2 | 3 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 2 | 2 |
| 2009 | 3 | 4 | 7 |
| 2010 | 3 | 7 | 10 |
| 2011 | 5 | 2 | 7 |
| 2012 | 6 | 5 | 11 |
| 2013 | 11 | 5 | 16 |
| 2014 | 3 | 5 | 8 |
| 2015 | 1 | 5 | 6 |
| 2016 | 2 | 12 | 14 |
| 2017 | 5 | 8 | 13 |
| 2018 | 4 | 10 | 14 |
| 2019 | 10 | 9 | 19 |
| 2020 | 5 | 8 | 13 |
| 2021 | 12 | 6 | 18 |
| 2022 | 2 | 15 | 17 |
| 2023 | 2 | 6 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoadjuvant Therapy" by people in Profiles.
-
Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023 Jul 27; 389(4):322-334.
-
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023 06 12; 41(6):1091-1102.e4.
-
Treatment Decisions for Resectable Non-Small-Cell Lung Cancer: Balancing Less With More? Am Soc Clin Oncol Educ Book. 2023 May; 43:e389950.
-
The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer. Breast Cancer Res Treat. 2023 Jul; 200(1):75-83.
-
Accuracy of models to prognosticate survival after surgery for pancreatic cancer in the era of neoadjuvant therapy. J Surg Oncol. 2023 Aug; 128(2):280-288.
-
Response to Treatment, Racial and Ethnic Disparity, and Survival in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy in the US. JAMA Netw Open. 2023 03 01; 6(3):e235834.
-
Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer. JAMA Netw Open. 2023 03 01; 6(3):e233329.
-
MRI assessment of rectal cancer response to neoadjuvant therapy: a multireader study. Eur Radiol. 2023 Aug; 33(8):5761-5768.
-
Oncologic end points and implication of trial design in the era of immunotherapy for resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 06; 165(6):1949-1953.
-
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial. JAMA Surg. 2022 11 01; 157(11):1034-1041.